Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection
Lung Infection
About this trial
This is an interventional treatment trial for Lung Infection focused on measuring pulmonary, mycobacterium avium complex infection, MAC, nontuberculous, mycobacteria, lung
Eligibility Criteria
Male and female patients, 18 years of age or older, with bacteriologically and radiographically confirmed pulmonary MAC infection who have been treated for their infection for at least 6 months within the previous 2 years, as well as patients with moderate or severe pulmonary disease due to MAC, not previously treated for this infection. Patients with recurrent pulmonary MAC infection after previous successful treatment for pulmonary MAC disease are also eligible. In addition, various laboratory testing must confirm conditions. Patients cannot be positive for HIV or have an extra-pulmonary (in general, outside of the lungs) infection of MAC. Other preconditions related to health or other conditions exist as factors for inclusion or exclusion from this study.